Neoadjuvant Atezolizumab Safe in Resectable Lung Cancer Neoadjuvant Atezolizumab Safe in Resectable Lung Cancer

In the LCMC3 study, patients received 1200 mg of neoadjuvant atezolizumab IV every 3 weeks for two cycles followed by resection between 30 and 50 days from the first cycle.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news